# Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

> **NCT00447057** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 204 (actual)

## Conditions studied

- Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Erlotinib
- **DRUG:** Pemetrexed
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00447057
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-07
- **Final completion:** 2011-06
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2011-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00447057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00447057, "Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00447057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*